Zydus Lifesciences Q2 FY27 Revenue Up 29% to ₹79,096 Mn
Zydus Lifesciences announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. For Q2 FY27, revenue from operations reached ₹79,096 million, a 29% increase year-on-year. R&D investments stood at ₹6,573 million (8.3% of revenues). EBITDA was ₹18,945 million, down 6% year-on-year, with an EBITDA margin of 24.0%. Net profit for the quarter was ₹9,255 million, a decrease of 27% year-on-year. Capex (organic) for the quarter was ₹4,655 million. For H1 FY27, revenue from operations was ₹1,59,266 million, up 25% year-on-year. Net profit for H1 FY27 was ₹18,859 million, down 31% year-on-year. The company highlighted strong momentum in branded businesses and a shift towards a specialty-led portfolio, with US branded sales rising to 16%.
Key Highlights
- Q2 FY27 revenue increased 29% YoY to ₹79,096 million.
- H1 FY27 revenue grew 25% YoY to ₹1,59,266 million.
- Q2 FY27 Net Profit declined 27% YoY to ₹9,255 million.
- H1 FY27 Net Profit fell 31% YoY to ₹18,859 million.
- R&D investment was 8.3% of revenues in Q2 FY27.
Price Impact
More from ZYDUSLIFE